Melatonin Secretion and Sleep Quality in Spinal Cord Injury Patients
MELATETRA
1 other identifier
observational
18
1 country
1
Brief Summary
To evaluate the relationship between secretion of melatonin and sleep quality in spinal cord injury patients versus a database of healthy volunteers.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Jul 2017
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 23, 2017
CompletedFirst Posted
Study publicly available on registry
May 30, 2017
CompletedStudy Start
First participant enrolled
July 11, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 31, 2018
CompletedStudy Completion
Last participant's last visit for all outcomes
July 31, 2018
CompletedAugust 17, 2018
July 1, 2018
1.1 years
May 23, 2017
August 16, 2018
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Urinary 6-sulfatoxy-melatonin (U6SM)
Urinary 6-sulfatoxy-melatonin (U6SM) will be measured during 24 hours
24 hours
Secondary Outcomes (2)
Sleep quality
24 hours
Daytime sleepiness
24 hours
Study Arms (2)
spinal cord injury
spinal cord injury all scores AIS
Healthy volunteers
Healthy volunteers for whom melatonin profiles have been taken and stored in the Lyon endocrinology laboratory's database. No healthy volunteers will be directly recruited for the study.
Eligibility Criteria
Spinal cord injury patients
You may qualify if:
- Male or female ≥ 18 years
- Spinal cord injury patient
- All score AIS
- With a chronic lesion (more than 6 months from initial injury)
- Signed informed consent
You may not qualify if:
- Pregnant women
- Breast feeding women
- Refusal to participate at study
- Not covered by national health insurance scheme
- Patient unable to give informed consent
- Transmeridian flight crossing more than 3 time zones in the month preceding the study
- Recent treatment with melatonin (\< 1 month) or beta blocker
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
APHP Hôpital Raymond poincaré
Garches, Île-de-France Region, 92380, France
Biospecimen
urinary samples
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Maria Antonia Quera-Salva, MD-PhD
APHP Hopital Raymond Poincare
- PRINCIPAL INVESTIGATOR
Raphaella Daville, MD
APHP Hopital Raymond Poincare
- STUDY CHAIR
Djamel BENSMAIL, MD-PhD
APHP Hopital Raymond Poincare
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 23, 2017
First Posted
May 30, 2017
Study Start
July 11, 2017
Primary Completion
July 31, 2018
Study Completion
July 31, 2018
Last Updated
August 17, 2018
Record last verified: 2018-07
Data Sharing
- IPD Sharing
- Will not share